New technologies for influenza vaccines

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 1, 2012, Pages 45-58

  Dormitzer, Philip R ^a   Tsai, Theodore F ^a   Del Giudice, Giuseppe ^b  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; AS 03; C REACTIVE PROTEIN; EPITOPE; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MIFAMURTIDE; PLACEBO; PREFLUCEL; UNCLASSIFIED DRUG; VIROSOME; VIRUS VECTOR; 2006 (H1N1) HEMAGGLUTININ FUSION PROTEIN; ADJUVANT INACTIVATED INFLUENZA VACCINE; FLAGELLIN; HYBRID PROTEIN; LIVE VECTORED INFLUENZA VACCINE; MAMMALIAN CELL CULTURE BASED INFLUENZA VACCINE; MF59 ADJUVANTED INFLUENZA VACCINE; OIL ADJUVANTED INFLUENZA VACCINE; PROTEIN M2E; QUADRIVALENT INFLUENZA VACCINE; RECOMBINANT SUBUNIT BASED INFLUENZA VACCINE; RECOMBINANT UNCLEAVED INFLUENZA VIRUS HEMAGGLUTININ; SALMONELLA TYPHIMURIUM TYPE 2 FLAGELLIN; TRIVALENT INACTIVATED INFLUENZA VACCINE; VIRUS HEMAGGLUTININ; VIRUS LIKE PARTICLE VACCINE; VIRUS PROTEIN;

ADJUVANT THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIBODY TITER; CELL CULTURE; DIMERIZATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNODIFFUSION; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC; PROTEIN PURIFICATION; RECOMBINANT DNA TECHNOLOGY; REVIEW; SEROCONVERSION; VACCINE PRODUCTION; VIRUS LIKE AGENT; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TRANSMISSION; ABSCESS; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG MEGADOSE; DRUG PURIFICATION; DRUG SYNTHESIS; ESCHERICHIA COLI; GENE; HEMAGGLUTININ GENE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFLAMMATION; INFLUENZA; LOW DRUG DOSE; MACRONEEDLE; MAMMAL CELL; MICRONEEDLE; NEEDLE; PANDEMIC INFLUENZA; POLYACRYLAMIDE GEL ELECTROPHORESIS; SALMONELLA TYPHIMURIUM; SINGLE DRUG DOSE; STERILE ABSCESS; VIRUS TITRATION;

EID: 84861823317     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.8.1.18859     Document Type: Review

References (187)

1. Francis T, Magill TP. The Antibody Response of Human Subjects Vaccinated with the Virus of Human Influenza. J Exp Med 1937; 65:251-9; PMID: 19870599; http://dx.doi.org/10.1084/jem.65.2.251
2. New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 2009; 84:249-57; PMID:19537358
3. Experiences with obtaining influenza vaccination among persons in priority groups during a vaccine shortage-United States, October-November, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:1153-5; PMID:15614228
4. Dormitzer PR. Cell culture-derived influenza vaccines. In: Del Giudice G, Rappuoli R, ed. Influenza Vaccines For the Future. Basel: Birkhauser Inc., 2010:293-312.
5. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009; 200:841-8; PMID:19673651; http://dx.doi.org/ 10.1086/605505
6. Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 2010; 28:840-8; PMID:19835829; http://dx. doi.org/10.1016/j.vaccine.2009.10.019
7. Ehrlich HJ, Muller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008; 358:2573-84; PMID:18550874; http://dx.doi.org/10.1056/ NEJMoa073121
8. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35; PMID:19745215; http://dx.doi.org/10.1056/NEJMoa0907650
9. Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009; 200:849-57; PMID:19673652; http://dx.doi.org/10. 1086/605506
10. Halperin SA, Smith B, Mabrouk T, Germain M, Trepanier P, Hassell T, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002; 20:1240-7; PMID:11803087; http://dx.doi.org/10.1016/S0264-410X(01) 00428-5
11. Palache AM, Scheepers HS, de Regt V, van Ewijk P, Baljet M, Brands R, et al. Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cellderived inactivated influenza subunit vaccine. A metaanalysis of clinical studies. Dev Biol Stand 1999; 98: 115-25, discussion 33-4; PMID:10494964
12. Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 1997; 176(Suppl 1):S20-3; PMID:9240689; http://dx.doi.org/10.1086/514169
13. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 2009; 27:786-91; PMID:19027046; http://dx.doi.org/ 10.1016/j.vaccine.2008.11.003
14. Halperin SA, Nestruck AC, Eastwood BJ. Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture. Vaccine 1998; 16:1331-5; PMID:9682398; http://dx.doi.org/10.1016/S0264-410X(98)00011-5
15. Ehrlich HJ, Muller M, Fritsch S, Zeitlinger M, Berezuk G, Low-Baselli A, et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009; 200:1113-8; PMID:19712040; http://dx.doi.org/10.1086/605608
16. Schild GC, Oxford JS, de Jong JC, Webster RG. Evidence for host-cell selection of influenza virus antigenic variants. Nature 1983; 303:706-9; PMID: 6190093; http://dx.doi.org/10.1038/303706a0
17. Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild GC. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 1985; 143:166-74; PMID: 4060580; http://dx.doi.org/10.1016/0042-6822(85) 90105-9
18. Widjaja L, Ilyushina N, Webster RG, Webby RJ. Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs. Virology 2006; 350:137-45; PMID:16545416; http://dx.doi.org/10.1016/j. virol.2006.02.020
19. Katz JM, Wang M, Webster RG. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol 1990; 64:1808-11; PMID:2319652
20. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Avian flu: influenza virus receptors in the human airway. Nature 2006; 440:435-6; PMID: 16554799; http://dx.doi.org/10.1038/440435a
21. Ito T, Suzuki Y, Takada A, Kawamoto A, Otsuki K, Masuda H, et al. Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol 1997; 71:3357-62; PMID:9060710
22. Minor PD, Engelhardt OG, Wood JM, Robertson JS, Blayer S, Colegate T, et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009; 27:2907-13; PMID:19366582; http://dx.doi.org/10.1016/j.vaccine. 2009.02.064
23. Meguro H, Bryant JD, Torrence AE, Wright PF. Canine kidney cell line for isolation of respiratory viruses. J Clin Microbiol 1979; 9:175-9; PMID:219021
24. Preliminary assessment of the effectiveness of the 2003-04 inactivated influenza vaccine-Colorado, December 2003. MMWR Morb Mortal Wkly Rep 2004; 53:8-11; PMID:14724559
25. Update: influenza-associated deaths reported among children aged, 18 years-United States, 2003-04 influenza season. MMWR Morb Mortal Wkly Rep 2004; 52:1286-8; PMID:14712178
26. Cox MM. Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Ther 2008; 10:56-61; PMID:18228182
27. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011; 29:2272-8; PMID: 21277410; http://dx.doi.org/10.1016/j.vaccine.2011. 01.039
28. Keitel WA, Treanor JJ, El Sahly HM, Gilbert A, Meyer AL, Patriarca PA, et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons . or =65 years old. Vaccine 2009; 28:379-85; PMID:19879222; http://dx.doi.org/10.1016/j.vaccine. 2009.10.037
29. King JC, Jr., Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 2009; 27:6589-94; PMID:19716456; http://dx.doi.org/10. 1016/j.vaccine.2009.08.032
30. Treanor JJ, Sahly HE, King J, Graham I, Izikson R, Kohberger R, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok((R))) against influenza in healthy adults: A randomized, placebo-controlled trial. Vaccine 2011; 29:7733-9; PMID:21835220; http://dx.doi.org/10. 1016/j.vaccine.2011.07.128
31. Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008; 198:635-41; PMID:18694338; http://dx.doi.org/10. 1086/590916
32. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006; 24:2176-85; PMID:16310896; http://dx.doi. org/10.1016/j.vaccine.2005.11.005
33. Tatu U, Hammond C, Helenius A. Folding and oligomerization of influenza hemagglutinin in the ER and the intermediate compartment. EMBO J 1995; 14:1340-8; PMID:7729412
34. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/ 34 hemagglutinin (H1 subtype). Cell 1982; 31:417- 27; PMID:6186384; http://dx.doi.org/10.1016/0092- 8674(82)90135-0
35. Wei CJ, Xu L, Kong WP, Shi W, Canis K, Stevens J, et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol 2008; 82: 6200-8; PMID:18417563; http://dx.doi.org/10.1128/ JVI.00187-08
36. Nestorowicz A, Laver G, Jackson DC. Antigenic determinants of influenza virus haemagglutinin. X. A comparison of the physical and antigenic properties of monomeric and trimeric forms. J Gen Virol 1985; 66: 1687-95; PMID:2410559; http://dx.doi.org/10.1099/ 0022-1317-66-8-1687
37. Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, Wilson IA. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 2004; 303:1866-70; PMID:14764887; http://dx.doi.org/10. 1126/science.1093373
38. Zhang W, Qi J, Shi Y, Li Q, Gao F, Sun Y, et al. Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. Protein Cell 2010; 1:459-67; PMID:21203961; http://dx.doi.org/10.1007/s13238-010-0059-1
39. Liu G, Tarbet B, Song L, Reiserova L, Weaver B, Chen Y, et al. Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS ONE 2011; 6:e20928; PMID:21687743; http://dx.doi.org/ 10.1371/journal.pone.0020928
40. Song L, Nakaar V, Kavita U, Price A, Huleatt J, Tang J, et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE 2008; 3:e2257; PMID:18493310; http://dx.doi.org/ 10.1371/journal.pone.0002257
41. Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, et al. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS ONE 2010; 5:e11548; PMID:20634959; http://dx.doi.org/10.1371/journal. pone.0011548
42. Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981; 289:373-8; PMID: 6162101; http://dx.doi.org/10.1038/289373a0
43. Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993; 67:2552-8; PMID:7682624
44. Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, et al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 2011; 29:4897-902; PMID:21596084; http://dx.doi.org/10. 1016/j.vaccine.2011.05.001
45. Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, Fitzgerald T, et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 2010; 28:8268-74; PMID:20969925; http://dx.doi. org/10.1016/j.vaccine.2010.10.009
46. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005; 23:5751-9; PMID:16143432; http://dx.doi.org/10.1016/j.vaccine.2005.07.098
47. D'Aoust MA, Lavoie PO, Couture MM, Trepanier S, Guay JM, Dargis M, et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 2008; 6:930-40; PMID:19076615; http://dx.doi.org/ 10.1111/j.1467-7652.2008.00384.x
48. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008; 3:e1501; PMID:18231588
49. Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, et al. H5N1 Virus-Like Particle Vaccine Elicits Cross-Reactive Neutralizing Antibodies That Preferentially Bind to the Oligomeric Form of Influenza Virus Hemagglutinin in Humans. J Virol 2011; 85:10945-54; PMID:21865396; http://dx.doi. org/10.1128/JVI.05406-11
50. López-Macias C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011; 29:7826-34; PMID:21816199; http:// dx.doi.org/10.1016/j.vaccine.2011.07.099
51. Landry N, Ward BJ, Trepanier S, Montomoli E, Dargis M, Lapini G, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 2010; 5: e15559; PMID:21203523; http://dx.doi.org/10.1371/ journal.pone.0015559
52. Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respi Viruses 2008; 2:193-202; PMID:19453395; http://dx.doi.org/10.1111/j.1750-2659.2008.00056.x
53. Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses 2011; 5:67-75; PMID:21306569; http://dx.doi.org/10.1111/j. 1750-2659.2010.00183.x
54. Patel SP, Jarvelin MR, Little MP. Systematic review of worldwide variations of the prevalence of wheezing symptoms in children. Environ Health 2008; 7:57; PMID:19000318; http://dx.doi.org/10.1186/1476-069X-7-57
55. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361:1260-7; PMID:19776407; http://dx.doi. org/10.1056/ NEJMoa0808652
56. Ohmit SE, Victor JC, Teich ER, Truscon RK, Rotthoff JR, Newton DW, et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 2008; 198:312-7; PMID:18522501; http://dx.doi.org/10.1086/589885
57. Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, et al. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis 2010; 201:354-62; PMID:20039806; http://dx.doi.org/10.1086/649428
58. Steel J, Lowen AC, Pena L, Angel M, Solorzano A, Albrecht R, et al. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 2009; 83:1742-53; PMID:19073731; http://dx. doi.org/10.1128/JVI.01920-08
59. Zhou B, Li Y, Belser JA, Pearce MB, Schmolke M, Subba AX, et al. NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets. Vaccine 2010; 28:8015-25; PMID:20934458; http://dx.doi. org/10.1016/j.vaccine.2010.08.106
60. Akarsu H, Iwatsuki-Horimoto K, Noda T, Kawakami E, Katsura H, Baudin F, et al. Structure-based design of NS2 mutants for attenuated influenza A virus vaccines. Virus Res 2011; 155:240-8; PMID:20970464; http:// dx.doi.org/10.1016/ j.virusres.2010.10.014
61. Kopecky-Bromberg SA, Palese P. Recombinant vectors as influenza vaccines. Curr Top Microbiol Immunol 2009; 333:243-67; PMID:19768410; http://dx.doi. org/10.1007/978-3-540-92165-3-13
62. Tang DC, Zhang J, Toro H, Shi Z, Van Kampen KR. Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines. Expert Rev Vaccines 2009; 8:469-81; PMID:19348562; http://dx.doi.org/10.1586/erv.09.1
63. Zhang J, Tarbet EB, Feng T, Shi Z, Van Kampen KR, Tang DC. Adenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenza. PLoS ONE 2011; 6:e22605; PMID: 21818346; http://dx.doi.org/10.1371/journal.pone. 0022605
64. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 2005; 23:1029-36; PMID: 15620476; http://dx.doi.org/10.1016/j.vaccine.2004. 07.043
65. Rimmelzwaan GF, Sutter G. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines 2009; 8:447-54; PMID:19348560; http://dx.doi.org/10.1586/erv.09.4
66. Gibson DG, Glass JI, Lartigue C, Noskov VN, Chuang RY, Algire MA, et al. Creation of a bacterial cell controlled by a chemically synthesized genome. Science 2010; 329:52-6; PMID:20488990; http://dx. doi.org/10.1126/science. 1190719
67. Hitchman RB, Locanto E, Possee RD, King LA. Optimizing the baculovirus expression vector system. Methods 2011; 55:52-7; PMID:21945427; http://dx. doi.org/10.1016/j.ymeth.2011.06.011
68. Chen R, Holmes EC. The evolutionary dynamics of human influenza B virus. J Mol Evol 2008; 66:655-63; PMID:18504518; http://dx.doi.org/10.1007/s00239- 008-9119-z
69. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 28(Suppl 4):D45-53; PMID:20713260; http://dx.doi.org/10.1016/j. vaccine. 2010.08.028
70. Meijer A, Meerhoff TJ, Meuwissen LE, van der Velden J, Paget WJ. Epidemiological and virological assessment of influenza activity in Europe during the winter 2005-2006. Euro Surveill 2007; 12:E11-2; PMID:17991413
71. Della Cioppa G, Vesikari T, Sokal E, Lindert K, Nicolay U. Trivalent and quadrivalent MF59((R))- adjuvanted influenza vaccine in young children: A dose- and schedule-finding study. Vaccine 2011; 29: 8696-704; PMID:21906647; http://dx.doi.org/10. 1016/j.vaccine.2011.08.111
72. Bandell A, Woo J, Coelingh K. Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference. Expert Rev Vaccines 2011; 10:1131-41; PMID:21854309; http://dx.doi.org/10.1586/erv.11.73
73. Hennessy AV, Davenport FM. Relative merits of aqueous and adjuvant influenza vaccines when used in a two-dose schedule. Public Health Rep 1961; 76:411-9; PMID:13713365; http://dx.doi.org/10.2307/4591160
74. Salk JE, Bailey ML, Laurent AM. The use of adjuvants in studies on influenza immunization. II. Increased antibody formation in human subjects inoculated with influenza virus vaccine in a water in-oil emulsion. Am J Hyg 1952; 55:439-56; PMID:14933383
75. Salk JE, Contakos M, Laurent AM, Sorensen M, Rapalski AJ, Simmons IH, et al. Use of adjuvants in studies on influenza immunization. III. Degree of persistence of antibody in human subjects two years after vaccination. J Am Med Assoc 1952; 151:1169- 75; PMID:13034453
76. Davis DJ, Philip RN, Bell JA, Vogel JE, Jensen DV. Epidemiologic studies on influenza in familial and general population groups. 1951-1956. III. Laboratory observations. Am J Hyg 1961; 73:138-47; PMID: 13720154
77. Davenport FM, Hennessy AV, Bell JA. Immunologic advantages of emulsified influenza virus vaccines. Mil Med 1962; 127:95-100; PMID:13883722
78. Beebe GW, Simon AH, Vivona S. Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953. Am J Epidemiol 1972; 95:337-46; PMID:5015584
79. Davenport FM, Hennessy AV, Askin FB. Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man. J Immunol 1968; 100:1139- 40; PMID:5648476
80. Werner J, Kuwert EK, Stegmaier R, Simbock H. [Local and systemic antibody response after vaccination with 3 different types of vaccines against influenza. II. Neuraminidase inhibiting antibodies (author's transl)]. Zentralbl Bakteriol A 1980; 246:1-9; PMID:7424233
81. D'Errico MM, Grasso GM, Romano F, Montanaro D. [Comparison of anti-influenza vaccines: whole adsorbed trivalent, trivalent subunit and tetravalent subunit]. Boll Ist Sieroter Milan 1988; 67:283-9; PMID:2482767
82. Ioniţeõ E, Lupulescu E, Alexandrescu V, Matepiuc M, Constantinescu C, Cretescu L, et al. Comparative study of the immunogenicity of aqueous versus aluminium phosphate adsorbed split influenza vaccine C.I. Arch Roum Pathol Exp Microbiol 1989; 48:265-73; PMID:2519636
83. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007; 6:699-710; PMID:17931151
84. Del Giudice G, Fragapane E, Bugarini R, Hora M, Henriksson T, Palla E, et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol 2006; 13:1010-3; PMID:16960112; http://dx.doi.org/10.1128/CVI. 00191-06
85. Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/ 1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/ 2002 than a subunit and a split influenza vaccine. Vaccine 2006; 24:3063-5; PMID:16464520; http:// dx.doi.org/10.1016/j. vaccine.2006.01.015
86. Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, et al. Cross-protection by MF59- adjuvanted influenza vaccine: neutralizing and haemagglutination- inhibiting antibody activity against A (H3N2) drifted influenza viruses. Vaccine 2008; 26: 1525-9; PMID:18294741; http://dx.doi.org/ 10.1016/ j.vaccine.2008.01.019
87. Camilloni B, Neri M, Lepri E, Iorio AM. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. Vaccine 2009; 27:4099-103; PMID:19410623; http://dx.doi.org/10.1016/j.vaccine. 2009.04.078
88. Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010; 10:639-51; PMID:20218923; http://dx.doi.org/10. 1517/14712591003724662
89. Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010; 28:4123-9; PMID:20433807; http://dx.doi.org/10.1016/j.vaccine. 2010.04.030
90. Baldo V, Baldovin T, Pellegrini M, Angiolelli G, Majori S, Floreani A, et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010; 2010:517198; PMID:20369059
91. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19:2673-80; PMID:11257408; http://dx.doi.org/10.1016/S0264-410X(00)00499-0
92. Puig-Barberà J, Díez-Domingo J, Varea A, Chavarri G, Rodrigo J, Hoyos S, et al. Effectiveness of MF59- adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 2007; 25:7313-21; PMID:17889411; http://dx.doi. org/10.1016/j.vaccine.2007.08.039
93. Mannino S, Villa M, Weiss N, Apolone G, Rothman K. Effectiveness of influenza vaccination with Fluad versus a sub-unit influenza vaccine. Am J Epidemiol 2010; 171:S157.
94. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008; 197:667-75; PMID:18260764; http://dx.doi.org/10.1086/527489
95. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 2009; 4:e4384; PMID:19197383; http://dx.doi.org/10.1371/journal.pone.0004384
96. Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M, et al. Impact of prior or concomitant seasonal influenza vaccination on MF59- adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract 2010; 64:432-8; PMID:20039974; http://dx.doi.org/10.1111/j.1742- 1241.2009.02309.x
97. Stephenson I, Nicholson KG, Hoschler K, Zambon MC, Hancock K, DeVos J, et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008; 359:1631-3; PMID:18843132; http://dx.doi.org/10.1056/ NEJMc0805274
98. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009; 106:7962-7; PMID: 19416838; http://dx.doi.org/10.1073/pnas. 0903181106
99. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant. Pediatr Infect Dis J 2009; 28:563-71; PMID:19561422; http://dx. doi.org/10.1097/INF.0b013e31819d6394
100. Vesikari T, Knuf M, Wutzler P. Efficacy of an MF59- Adjuvanted seasonal influenza vaccine versus nonadjuvanted influenza vaccine and control vaccine in 6 to < 72 month old children. 2010.
101. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011; 365:1406-16; PMID: 21995388; http://dx.doi.org/10.1056/ NEJMoa1010331
102. Vogel FR, Caillet C, Kusters IC, Haensler J. Emulsionbased adjuvants for influenza vaccines. Expert Rev Vaccines 2009; 8:483-92; PMID:19348563; http:// dx.doi.org/10.1586/erv.09.5
103. Leroux-Roels G, Clement F, Leroux-Roels I, Drame M, Moris P, Devaster JM. Adjuvanted influenza vaccines improve anti-influenza cellular mediated immunity impaired in elderly. Presented at: Influenza Vaccines for the World, October 18-20, 2006; Vienna, Austria 2006.
104. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29:2461-73; PMID:21256188; http:// dx.doi.org/10.1016/j.vaccine.2011.01.011
105. Leroux-Roels I, Leroux-Roels G. Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev Vaccines 2009; 8:401-23; PMID:19348557; http://dx.doi.org/10.1586/erv.09.15
106. Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03Aadjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011; 11:91-101; PMID:21168369; http://dx.doi.org/10.1016/S1473-3099(10)70296-6
107. Meier S, Bel M, L'Huillier A, Crisinel PA, Combescure C, Kaiser L, et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 2011; 29:3548-57; PMID:21419775; http:// dx.doi.org/10.1016/j. vaccine.2011.02.094
108. Rahier JF, Papay P, Salleron J, Sebastian S, Marzo M, Peyrin-Biroulet L, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011; 60:456-62; PMID: 21270121; http://dx.doi.org/10.1136/gut.2010.233981
109. National Institute for Health and Welfare Finland. National narcolespy task force interim report. Helsinki, Finland, 2011.
110. World Health Organization. Global Advisory Committee on Vaccine Safety. Statement on narcolepsy and vaccination. Geneva: WHO, 2011.
111. Dauvilliers Y, Montplaisir J, Cochen V, Desautels A, Einen M, Lin L, et al. Post-H1N1 narcolepsycataplexy. Sleep 2010; 33:1428-30; PMID:21102981
112. Tsai TF, Crucitti A, Nacci P, Nicolay U, Della Cioppa G, Ferguson J, et al. Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011; 43:702-6; PMID:21534891
113. Poland GA, Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn A, Vandermeulen C, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces crossreactive immune responses in healthy adults. J Infect Dis 2008; 198:629-31; PMID:18694337; http://dx. doi.org/10.1086/590913
114. Panda A, Arjona A, Sapey E, Bai F, Fikrig E, Montgomery RR, et al. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol 2009; 30:325-33; PMID:19541535; http://dx.doi.org/10.1016/j.it.2009.05. 004
115. Farage MA, Miller KW, Berardesca E, Maibach HI. Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol 2009; 10:73-86; PMID:19222248; http://dx.doi.org/10. 2165/00128071-200910020-00001
116. Halperin W, Weiss WI, Altman R, Diamond MA, Black KJ, Iaci AW, et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/ 75: report of a study and review of the literature. Am J Public Health 1979; 69:1247-51; PMID:507256; http://dx.doi.org/10.2105/AJPH.69.12.1247
117. Brown H, Kasel JA, Freeman DM, Moise LD, Grose NP, Couch RB. The immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. J Infect Dis 1977; 136(Suppl):S466-71; PMID:606768; http://dx. doi.org/10.1093/infdis/136. Supplement-3.S466
118. Herbert FA, Larke RP, Markstad EL. Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease. J Infect Dis 1979; 140:234-8; PMID:479641; http://dx. doi.org/10.1093/infdis/140.2.234
119. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351:2286-94; PMID:15525713; http://dx.doi. org/10.1056/NEJMoa043555
120. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351:2295-301; PMID: 15525714; http://dx.doi.org/10.1056/NEJMoa043540
121. Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007; 25:659-63; PMID:17011678; http://dx.doi.org/10.1016/ j.vaccine.2006.08.026
122. Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine 2008; 26:6614-9; PMID:18930093; http:// dx.doi.org/10.1016/j.vaccine.2008.09.078
123. Beran J, Ambrozaitis A, Laiskonis A, Mickuviene N, Bacart P, Calozet Y, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med 2009; 7:13; PMID: 19341446; http://dx.doi.org/10.1186/1741-7015- 7-13
124. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009; 27:454-9; PMID:19022318; http://dx. doi.org/10.1016/j.vaccine.2008.10.077
125. Gelinck LB, van den Bemt BJ, Marijt WA, van der Bijl AE, Visser LG, Cats HA, Rimmelzwaan GF, et al. Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible. Vaccine 2009; 27:2469-74; PMID:19368788
126. Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007; 25:6755-63; PMID:17692438; http:// dx.doi.org/10.1016/j.vaccine.2007.06.066
127. Treanor J, Keitel W, Belshe R, Campbell J, Schiff G, Zangwill K, et al.
128. Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med 2008; 168:2405-14; PMID:19064822; http://dx.doi. org/10.1001/archinternmed.2008.513
129. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198:650-8; PMID:18652550; http://dx.doi.org/ 10.1086/590434
130. Van Damme P, Arnou R, Kafeja F, Fiquet A, Richard P, Thomas S, et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis 2010; 10:134; PMID:20504306; http://dx.doi.org/10.1186/ 1471- 2334-10-134
131. Ansaldi F, Durando P, Icardi G. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin Biol Ther 2011; 11:415-27; PMID:21299438; http://dx.doi.org/10. 1517/14712598.2011.557658
132. Frenck RW, Jr., Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(R)) administered by intradermal and intramuscular route in healthy adults. Vaccine 2011; 29:5666-74; PMID:21699951; http:// dx.doi.org/10.1016/j.vaccine.2011.06.010
133. Patel SM, Atmar RL, El Sahly HM, Cate TR, Keitel WA. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine 2010; 28:3025-9; PMID:19931380; http://dx.doi.org/10.1016/j.vaccine. 2009.10.152
134. Weldon WC, Martin MP, Zarnitsyn V, Wang B, Koutsonanos D, Skountzou I, et al. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin Vaccine Immunol 2011; 18:647-54; PMID: 21288996; http://dx.doi.org/10.1128/CVI.00435-10
135. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010; 16:915-20; PMID:20639891; http:// dx.doi.org/10.1038/nm.2182
136. Glenn GM, Flyer DC, Ellingsworth LR, Frech SA, Frerichs DM, Seid RC, et al. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev Vaccines 2007; 6:809-19; PMID:17931160; http:// dx.doi.org/10.1586/14760584.6.5.809
137. Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008; 371:2019-25; PMID:18554712; http://dx.doi. org/10.1016/S0140-6736(08)60839-9
138. Guebre-Xabier M, Hammond SA, Ellingsworth LR, Glenn GM. Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice. J Virol 2004; 78:7610-8; PMID:15220436; http://dx.doi.org/10.1128/JVI.78.14.7610-7618. 2004
139. Frech SA, Kenney RT, Spyr CA, Lazar H, Viret JF, Herzog C, et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 2005; 23:946-50; PMID: 15603897; http://dx.doi.org/10.1016/j.vaccine.2004. 06.036
140. Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006; 80:4962-70; PMID:16641287; http:// dx.doi.org/10.1128/JVI.80.10.4962-4970.2006
141. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004; 350:896-903; PMID: 14985487; http://dx.doi.org/10.1056/NEJMoa030595
142. Bodewes R, Kreijtz JH, van Amerongen G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF, et al. Pathogenesis of Influenza A/H5N1 virus infection in ferrets differs between intranasal and intratracheal routes of inoculation. Am J Pathol 2011; 179:30-6; PMID:21640972; http://dx.doi.org/10.1016/j.ajpath. 2011.03.026
143. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 2009; 4:e6999; PMID:19756141; http:// dx.doi.org/10.1371/journal.pone.0006999
144. Amorij JP, Hinrichs W, Frijlink HW, Wilschut JC, Huckriede A. Needle-free influenza vaccination. Lancet Infect Dis 2010; 10:699-711; PMID:20883966; http:// dx.doi.org/10.1016/S1473-3099(10)70157-2
145. Schild GC, Wood JM, Newman RW. A single-radialimmunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull World Health Organ 1975; 52:223-31; PMID: 816480
146. Johannsen R, Hinz J, Gruschkau H. Pitfalls of single radial immunodiffusion techniques used for the quantification of influenza haemagglutinin. Dev Biol Stand 1986; 65:255-60; PMID:3104116
147. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35; PMID:19745215
148. Kapteyn JC, Porre AM, de Rond EJ, Hessels WB, Tijms MA, Kessen H, et al. HPLC-based quantification of haemagglutinin in the production of eggand MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 2009; 27:1468-77; PMID: 19110022; http://dx.doi.org/10.1016/j.vaccine.2008. 11.113
149. Lorbetskie B, Wang J, Gravel C, Allen C, Walsh M, Rinfret A, et al. Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. Vaccine 2011; 29:3377-89; PMID:21397719; http://dx.doi.org/10. 1016/j.vaccine.2011.02.090
150. Williams TL, Luna L, Guo Z, Cox NJ, Pirkle JL, Donis RO, et al. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008; 26:2510-20; PMID:18440105; http://dx.doi.org/10. 1016/j.vaccine.2008.03.014
151. Li C, Jaentschke B, Song Y, Wang J, Cyr TD, Van Domselaar G, et al. A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide. Nat Protoc 2010; 5:14-9; PMID: 20010723; http://dx.doi.org/10.1038/nprot.2009. 200
152. Nilsson CE, Abbas S, Bennemo M, Larsson A, Hamalainen MD, Frostell-Karlsson A. A novel assay for influenza virus quantification using surface plasmon resonance. Vaccine 2010; 28:759-66; PMID:19857452; http://dx.doi.org/10.1016/j.vaccine.2009.10.070
153. Hendry RM, Herrmann JE. Detection and identification of influenza virus antigens by nylon-coupled enzyme-linked immunoassay. J Virol Methods 1983; 6:9-17; PMID:6339533; http://dx.doi.org/10.1016/ 0166-0934(83)90063-0
154. Legastelois I, Chevalier M, Bernard MC, de Montfort A, Fouque M, Pilloud A, et al. Avian glycan-specific IgM monoclonal antibodies for the detection and quantitation of type A and B haemagglutinins in eggderived influenza vaccines. J Virol Methods 2011; 178:129-36; PMID:21907241; http://dx.doi.org/10. 1016/j.jviromet.2011.08.027
155. Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, et al. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 2007; 3:157-64; PMID:17637571; http://dx.doi.org/10. 4161/hv.3.5.4175
156. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, et al. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009; 27:6512-21; PMID:19729082; http:// dx.doi.org/10.1016/j.vaccine.2009.08.053
157. Wraith DC, Vessey AE, Askonas BA. Purified influenza virus nucleoprotein protects mice from lethal infection. J Gen Virol 1987; 68:433-40; PMID: 3493324; http://dx.doi.org/10.1099/0022-1317-68- 2-433
158. Rao SS, Kong WP, Wei CJ, Van Hoeven N, Gorres JP, Nason M, et al. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS ONE 2010; 5:e9812; PMID:20352112; http://dx.doi. org/10.1371/journal.pone.0009812
159. Plotnicky H, Cyblat-Chanal D, Aubry JP, Derouet F, Klinguer-Hamour C, Beck A, et al. The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K (b) transgenic mice. Virology 2003; 309:320-9; PMID:12758178; http://dx.doi.org/10.1016/S0042- 6822(03)00072-2
160. Adar Y, Singer Y, Levi R, Tzehoval E, Perk S, Banet- Noach C, et al. A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 2009; 27:2099-107; PMID:19356612; http://dx.doi.org/10. 1016/j.vaccine.2009.02. 011
161. Taylor PM, Askonas BA. Influenza nucleoproteinspecific cytotoxic T-cell clones are protective in vivo. Immunology 1986; 58:417-20; PMID:2426185
162. Sui Z, Chen Q, Fang F, Zheng M, Chen Z. Crossprotection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 2010; 28:7690-8; PMID:20870054; http://dx.doi.org/10. 1016/j.vaccine.2010.09.019
163. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309:13-7; PMID:6602294; http://dx.doi.org/ 10.1056/NEJM198307073090103
164. Russell SM, Liew FY. T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin. Nature 1979; 280:147-8; PMID:317881; http://dx.doi.org/10. 1038/280147a0
165. Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008; 451:591-5; PMID:18235503; http://dx.doi.org/10. 1038/nature06531
166. Stouffer AL, Acharya R, Salom D, Levine AS, Di Costanzo L, Soto CS, et al. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 2008; 451:596-9; PMID:18235504; http://dx.doi.org/10. 1038/nature06528
167. De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 2008; 283:11382-7; PMID:18252707; http:// dx.doi.org/10.1074/jbc. M800650200
168. Grandea AG, 3rd, Olsen OA, Cox TC, Renshaw M, Hammond PW, Chan-Hui PY, et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci USA 2010; 107:12658-63; PMID:20615945; http://dx.doi.org/10.1073/pnas. 0911806107
169. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibodydependent NK cell activity. J Immunol 2004; 172:5598-605; PMID:15100303
170. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5:1157-63; PMID:10502819; http://dx. doi.org/10.1038/ 13484
171. Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 2002; 83:1851-9; PMID: 12124449
172. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011; 29: 5145-52; PMID:21624416; http://dx.doi.org/10.1016/ j.vaccine.2011.05.041
173. AGGLUTINATION-INHIBITION test proposed as a standard of reference in influenza diagnostic studies; Committee on Standard Serological Procedures in Influenza Studies. J Immunol 1950; 65:347-53; PMID:14774517
174. Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci USA 2011; 108:14216-21; PMID:21825125; http://dx.doi.org/10.1073/pnas.1111497108
175. Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, Kida H, et al. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog 2009; 5:e1000350; PMID:19300497; http://dx.doi.org/10.1371/journal. ppat.1000350
176. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246-51; PMID:19251591; http:// dx.doi.org/10.1126/science. 1171491
177. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011; 333:843-50; PMID:21737702; http:// dx.doi.org/10.1126/science.1204839
178. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265-73; PMID: 19234466; http://dx.doi.org/10.1038/nsmb.1566
179. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850-6; PMID:21798894; http://dx.doi.org/10.1126/science. 1205669
180. Okuno Y, Matsumoto K, Isegawa Y, Ueda S. Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol 1994; 68:517-20; PMID: 8254764
181. Koudstaal W, Koldijk MH, Brakenhoff JP, Cornelissen LA, Weverling GJ, Friesen RH, et al. Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir. J Infect Dis 2009; 200:1870-3; PMID:19911992; http://dx.doi. org/10.1086/648378
182. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. M Bio 2010; 1:18-10; PMID:20689752
183. Kwong PD, Mascola JR, Nabel GJ. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med 2011; 1: a007278.
184. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010; 329:1060-4; PMID:20647428; http://dx.doi.org/10.1126/science. 1192517
185. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11:916-924; PMID:21975270
186. Corti D, Suguitan AL, Jr., Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010; 120:1663-73; PMID: 20389023; http://dx.doi.org/10.1172/JCI41902
187. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208:181-93; PMID:21220454; http://dx. doi.org/10.1084/jem.20101352